CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
The purpose of this study is to determine the safety and efficacy of immunotherapy durvalumab and tremelimumab combined with DEB-TACE in patients with Hepatocellular Carcinoma.
Intermediate Stage of Hepatocellular Carcinoma|Hepatocellular Carcinoma
DRUG: Durvalumab|DRUG: Tremelimumab (Cohort A dose)|DRUG: Tremelimumab (Cohort B dose)
Objective response rate (ORR) using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria., Proportion of participants with reduction in tumor burden as defined by mRECIST criteria., 2 years
Progression free survival (PFS), Number of months until disease progression or death, 2 years|Tumor response as determined by number of participants with partial (PR) or complete response (CR) as defined by mRECIST criteria, PR is defined as \>=30% reduction in size of target lesions, whereas CR is defined as disappearance of all target lesions, 2 years|Overall Survival (OS), Number of months until death from any-cause, 2 years|Number of participants experiencing study drug-related toxicities, Number of participants experiencing drug-related adverse events \>= Grade 3 or higher as defined by CTCAE v5.0, 2 years
The purpose of this study is to determine the safety and efficacy of immunotherapy durvalumab and tremelimumab combined with DEB-TACE in patients with Hepatocellular Carcinoma.